Transaction, investment facility update
Released
Released
Announcement PDF
ASX Announcement | 2 September 2024
AdAlta Limited (ASX:1AD)
Transaction progress, timing of 2nd institutional investment
AdAlta to receive $1 million from existing investment facility as transactions
advance
Highlights
•
•
•
Multiple term sheets being negotiated in respect of AdSolis (AD-214) and AdCella (East to West
cellular immunotherapies) strategies
$0.7 million proceeds of second investment by New Life Sciences Capital LLC to be received by
2 November
$0.3 million proceeds of second investment by Meurs Group to be received by 30 September
AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”) is pleased to confirm it is advancing
negotiations of several term sheets in respect of transactions associated with its AdSolis (AD-214) and
AdCella (East to West cellular immunotherapies) strategies and will receive second investments totaling
$1.0 million under the previously announced institutional investments by New Life Sciences Capital, LLC
(“NLSC”) and the Meurs Group (together, “Investors”).
AdAlta CEO and Managing Director, Tim Oldham said: "We are pleased with the progress being made
towards transactions in both our AdCella and AdSolis business units, enabled by the support of New Life
Sciences Capital and the Meurs Group. We look forward to updating shareholders on further progress over
coming months that will unambiguously demonstrate the true value of our i-body® platform."
AdAlta is in discussions with potential out-licensing partners and investors in its AdSolis subsidiary to
advance AD-214, its first in class asset taking a new approach to fibrotic diseases suchas Idiopathic
Pulmonary Fibrosis, into Phase II clinical trials. AdAlta, with its partner SYNthesis BioVentures, is also
evaluating several advanced cellular immunotherapy products from Asia for in-licensing to its AdCella
subsidiary as part of its “East to West” cellular immunotherapy strategy. Several of these discussions have
advanced to term sheet negotiation stage, following which final due diligence and contract negotiation can
occur.
On 29 April 2024, AdAlta announced an institutional investment of up to $3 million (the “NLSC Investment”)
by NLSC and up to $0.7 million (the “Meurs Investment”) by an entity associated with an existing
shareholder, the Meurs Group. The investments comprised multiple tranches, each by way of pre-payment
for fully paid ordinary shares (“Shares”) in the Company (“Placement Shares”). The first $0.8 million of the
NLSC Investment and the first $0.7 million of the Meurs Investment were received in May 2024. The
Company has the right, subject to certain conditions, to require NLSC to make a second investment of up to
$1.4 million (of which $0.7 million requires further NLSC consent) for Placement Shares worth $1.526 million
and Meurs Group to make a second investment of up to $0.3 million for Placement Shares worth $0.327
million. Full details of the terms of the NLSC Investment and the Meurs Investment can be found in the
Company’s ASX release of 29 April 2024. 1
1
https://investorhub.adalta.com.au/announcements/6310002
AdAlta Limited (ASX:1AD)
15/2 Park Drive, Bundoora 3083 Victoria Australia
ABN: 92 120 332 925
www.adalta.com.au
1
The Company has now exercised its right to the second investments and will receive $0.3 million from the
Meurs Investment by 30 September 2024 and $0.7 million from the NLSC Investment by 2 November 2024.
Proceeds will be used to progress the AdSolis and AdCella transactions outlined above.
The Company utilised its existing and available placement capacity under Listing Rule 7.1 to request the
second investments.
For a summary of this release and opportunity to engage in a virtual discussion see:
https://investorhub.adalta.com.au/link/aP3ooP
This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).
For further information, please contact:
AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au
Media & Investor Enquiries
The Capital Network
Julia Maguire
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au
2
About AdAlta Limited
AdAlta Limited (ASX:1AD) is a clinical stage drug development company headquartered in Melbourne,
Australia. The Company is using its proprietary i-body® technology platform to solve challenging drug
targeting problems and generate a promising new class of single domain antibody-enabled protein and cell
therapeutics with the potential to treat some of today’s most challenging medical conditions.
The i-body® technology creates a range of unique proteins capable of interacting with high selectivity,
specificity and affinity with previously difficult to access targets such as G-protein coupled receptors
(GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain
antibody scaffold and the first based on the shark motif to reach clinical trials.
AdAlta’s strategy is to maximise the products developed using its next generation i-body® platform by
discovering and developing selected i-body®-enabled product candidates useful in fibrosis, inflammation and
cancer; and partnering with other biopharmaceutical companies to develop these and other product
candidates in a range of indications and product formats
AdAlta’s current lead i-body® enabled candidate is AD-214, which is taking a wholly new approach to treat
lung fibrosis (IPF) and other fibrotic diseases. In accord with its business model, AdAlta is creating a private,
unlisted subsidiary called AdSolis to advance AD-214 into Phase II clinical trials through licensing and/or
third-party investment.
AdAlta believes that the i-body® technology is ideally suited for use in the creation of advanced cellular
immunotherapies for cancer and that this field represents an opportunity to expand its clinical stage pipeline.
It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of
a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular
immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials
and further enhancement with AdAlta’s i-body® technology.
The Company is also entering collaborative discovery partnerships to advance the development of its ibody® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body®
enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with
GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a
biomarker of response to immuno-oncology drugs, a program now in preclinical development.
For more information
Join our InvestorHub
Follow us on Twitter
Follow us on LinkedIn
To learn more about AdAlta please click here: www.adalta.com.au
3
Share your feedback
Discover